{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T23:48:25Z","timestamp":1795132105620,"version":"4.10.3"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,3,7]]},"abstract":"<jats:sec id=\"ab-joi230012-4\"><jats:title>Importance<\/jats:title><jats:p>In January 2011, the US Food and Drug Administration (FDA) announced a mandate to limit acetaminophen (paracetamol) to 325 mg\/tablet in combination acetaminophen and opioid medications, with manufacturer compliance required by March 2014.<\/jats:p><\/jats:sec><jats:sec id=\"ab-joi230012-5\"><jats:title>Objective<\/jats:title><jats:p>To assess the odds of hospitalization and the proportion of acute liver failure (ALF) cases with acetaminophen and opioid toxicity prior to and after the mandate.<\/jats:p><\/jats:sec><jats:sec id=\"ab-joi230012-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This interrupted time-series analysis used hospitalization data from 2007-2019 involving <jats:italic>ICD-9<\/jats:italic>\/<jats:italic>ICD-10<\/jats:italic> codes consistent with both acetaminophen and opioid toxicity from the National Inpatient Sample (NIS), a large US hospitalization database, and ALF cases from 1998-2019 involving acetaminophen and opioid products from the Acute Liver Failure Study Group (ALFSG), a cohort of 32 US medical centers. For comparison, hospitalizations and ALF cases consistent with acetaminophen toxicity alone were extracted from the NIS and ALFSG.<\/jats:p><\/jats:sec><jats:sec id=\"ab-joi230012-7\"><jats:title>Exposures<\/jats:title><jats:p>Time prior to and after the FDA mandate limiting acetaminophen to 325 mg in combination acetaminophen and opioid products.<\/jats:p><\/jats:sec><jats:sec id=\"ab-joi230012-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Odds of hospitalization involving acetaminophen and opioid toxicity and percentage of ALF cases from acetaminophen and opioid products prior to and after the mandate.<\/jats:p><\/jats:sec><jats:sec id=\"ab-joi230012-9\"><jats:title>Results<\/jats:title><jats:p>In the NIS, among 474\u202f047\u202f585 hospitalizations from Q1 2007 through Q4 2019, there were 39\u202f606 hospitalizations involving acetaminophen and opioid toxicity; 66.8% of cases were among women; median age, 42.2 (IQR, 28.4-54.1). In the ALFSG, from Q1 1998 through Q3 2019, there were a total of 2631 ALF cases, of which 465 involved acetaminophen and opioid toxicity; 85.4% women; median age, 39.0 (IQR, 32.0-47.0). The predicted incidence of hospitalizations 1 day prior to the FDA announcement was 12.2 cases\/100\u202f000 hospitalizations (95% CI, 11.0-13.4); by Q4 2019, it was 4.4\/100\u202f000 hospitalizations (95% CI, 4.1-4.7) (absolute difference, 7.8\/100\u202f000 [95% CI, 6.6-9.0]; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). The odds of hospitalizations with acetaminophen and opioid toxicity increased 11%\/y prior to the announcement (odds ratio [OR], 1.11 [95% CI, 1.06-1.15]) and decreased 11%\/y after the announcement (OR, 0.89 [95% CI, 0.88-0.90]). The predicted percentage of ALF cases involving acetaminophen and opioid toxicity 1 day prior to the FDA announcement was 27.4% (95% CI, 23.3%-31.9%); by Q3 2019, it was 5.3% (95% CI, 3.1%-8.8%) (absolute difference, 21.8% [95% CI, 15.5%-32.4%]; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). The percentage of ALF cases involving acetaminophen and opioid toxicity increased 7% per year prior to the announcement (OR, 1.07 [95% CI, 1.03-1.1]; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) and decreased 16% per year after the announcement (OR, 0.84 [95% CI, 0.77-0.92]; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). Sensitivity analyses confirmed these findings.<\/jats:p><\/jats:sec><jats:sec id=\"ab-joi230012-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The FDA mandate limiting acetaminophen dosage to 325 mg\/tablet in prescription acetaminophen and opioid products was associated with a statistically significant decrease in the yearly rate of hospitalizations and proportion per year of ALF cases involving acetaminophen and opioid toxicity.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jama.2023.1080","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T11:31:48Z","timestamp":1678188708000},"page":"735","source":"Crossref","is-referenced-by-count":30,"title":["Association of FDA Mandate Limiting Acetaminophen (Paracetamol) in Prescription Combination Opioid Products and Subsequent Hospitalizations and Acute Liver Failure"],"prefix":"10.1001","volume":"329","author":[{"given":"Babak J.","family":"Orandi","sequence":"first","affiliation":[{"name":"University of Alabama at Birmingham Heersink School of Medicine"},{"name":"Joan & Sanford Weill Medical College of Cornell University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Chandler","family":"McLeod","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham Heersink School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"MacLennan","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham Heersink School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center at Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fontana","sequence":"additional","affiliation":[{"name":"University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine J.","family":"Karvellas","sequence":"additional","affiliation":[{"name":"University of Alberta School of Medicine, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan M.","family":"McGuire","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham Heersink School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora E.","family":"Lewis","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham School of Public Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah M.","family":"Terrault","sequence":"additional","affiliation":[{"name":"University of Southern California Keck School of Medicine, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayme E.","family":"Locke","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham Heersink School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"US Acute Liver Failure Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M","family":"Larson","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Liou","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren","family":"Fix","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schilsky","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"McCashland","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Eileen","family":"Hay","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Murray","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obaid S.","family":"Shaikh","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Blei","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ganger","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atif","family":"Zaman","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H. B.","family":"Han","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Smith","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roert","family":"Brown","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Crippin","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Harrison","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Reuben","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Munoz","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajender","family":"Reddy","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Todd","family":"Stravitz","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Rossaro","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Satyanarayana","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Hassanein","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine J.","family":"Karvellas","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Olson","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Subramanian","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hanje","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Hameed","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Samuel","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Exmina","family":"Lalani","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Pezzia","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corron","family":"Sanders","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Attar","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda S.","family":"Hynan","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Durkalski","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenle","family":"Zhao","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Speiser","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Dillon","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Battenhouse","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Gottfriend","sequence":"additional","affiliation":[{"name":"for the US Acute Liver Failure Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"joi230012r1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016.","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recomm Rep"},{"issue":"22","key":"joi230012r2","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1056\/NEJMp0908913","article-title":"A difficult balance\u2014pain management, drug safety, and the FDA.","volume":"361","author":"Woodcock","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"joi230012r3","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1002\/(ISSN)1527-3350","article-title":"Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study.","volume":"42","author":"Larson","year":"2005","journal-title":"Hepatology"},{"issue":"12","key":"joi230012r4","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1016\/j.cgh.2020.09.016","article-title":"Clinical and neurologic outcomes in acetaminophen-induced acute liver failure: a 21-year multicenter cohort study.","volume":"19","author":"MacDonald","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"joi230012r5","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jhep.2017.07.005","article-title":"Acetaminophen (APAP) hepatotoxicity\u2014isn\u2019t it time for APAP to go away?","volume":"67","author":"Lee","year":"2017","journal-title":"J Hepatol"},{"issue":"8","key":"joi230012r6","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1080\/15563650903232345","article-title":"The FDA Acetaminophen Advisory Committee meeting\u2014what is the future of acetaminophen in the United States? the perspective of a committee member.","volume":"47","author":"Krenzelok","year":"2009","journal-title":"Clin Toxicol (Phila)"},{"issue":"3","key":"joi230012r7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/clpt.2010.164","article-title":"The case for limiting acetaminophen-related deaths: smaller doses and unbundling the opioid-acetaminophen compounds.","volume":"88","author":"Lee","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"joi230012r9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1526-4637.2010.00811.x","article-title":"Removal of opioid\/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications.","volume":"11","author":"Michna","year":"2010","journal-title":"Pain Med"},{"issue":"6","key":"joi230012r10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1001\/jama.2014.716","article-title":"FDA asks physicians to stop prescribing high-dose acetaminophen products.","volume":"311","author":"Mitka","year":"2014","journal-title":"JAMA"},{"key":"joi230012r11","doi-asserted-by":"publisher","first-page":"g356","DOI":"10.1136\/bmj.g356","article-title":"FDA acts to limit exposure to acetaminophen in combination products.","volume":"348","author":"McCarthy","year":"2014","journal-title":"BMJ"},{"issue":"2","key":"joi230012r14","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/hep.v60.2","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.","volume":"60","author":"Vilstrup","year":"2014","journal-title":"Hepatology"},{"issue":"9","key":"joi230012r15","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/s41395-018-0160-2","article-title":"Acute liver failure of indeterminate etiology: a comprehensive systematic approach by an expert committee to establish causality.","volume":"113","author":"Ganger","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"joi230012r16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1472-6963-7-159","article-title":"Validation of ICD-9-CM\/ICD-10 coding algorithms for the identification of patients with acetaminophen overdose and hepatotoxicity using administrative data.","volume":"7","author":"Myers","year":"2007","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"joi230012r17","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end-stage liver disease.","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"issue":"10","key":"joi230012r18","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa0801209","article-title":"Hyponatremia and mortality among patients on the liver-transplant waiting list.","volume":"359","author":"Kim","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"joi230012r19","first-page":"348","article-title":"Interrupted time series regression for the evaluation of public health interventions: a tutorial.","volume":"46","author":"Bernal","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"4","key":"joi230012r20","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1093\/ije\/dyt092","article-title":"Time series regression studies in environmental epidemiology.","volume":"42","author":"Bhaskaran","year":"2013","journal-title":"Int J Epidemiol"},{"issue":"5","key":"joi230012r21","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1097\/BPO.0000000000001143","article-title":"Current state of the opioid epidemic as it pertains to pediatric orthopaedics from the Advocacy Committee of the Pediatric Orthopaedic Society of North America.","volume":"38","author":"Raney","year":"2018","journal-title":"J Pediatr Orthop"},{"issue":"6","key":"joi230012r24","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1001\/jamainternmed.2014.7856","article-title":"Trends in the use of percutaneous ventricular assist devices: analysis of national inpatient sample data, 2007 through 2012.","volume":"175","author":"Khera","year":"2015","journal-title":"JAMA Intern Med"},{"key":"joi230012r25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1472-6904-12-11","article-title":"Population prevalence of high dose paracetamol in dispensed paracetamol\/opioid prescription combinations: an observational study.","volume":"12","author":"Clark","year":"2012","journal-title":"BMC Clin Pharmacol"},{"issue":"7-8","key":"joi230012r26","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1345\/aph.1P012","article-title":"A population study of the frequency of high-dose acetaminophen prescribing and dispensing.","volume":"44","author":"Albertson","year":"2010","journal-title":"Ann Pharmacother"},{"issue":"1","key":"joi230012r27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1001\/jama.296.1.87","article-title":"Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial.","volume":"296","author":"Watkins","year":"2006","journal-title":"JAMA"},{"issue":"12","key":"joi230012r28","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/pds.3350","article-title":"Prevalence and correlates of exceeding the labeled maximum dose of acetaminophen among adults in a U.S.-based internet survey.","volume":"21","author":"Kaufman","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"joi230012r29","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s11606-012-2096-3","article-title":"Risk of unintentional overdose with non-prescription acetaminophen products.","volume":"27","author":"Wolf","year":"2012","journal-title":"J Gen Intern Med"},{"issue":"5","key":"joi230012r30","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/bcp.v85.5","article-title":"Five-year trends in acetaminophen use exceeding the recommended daily maximum dose.","volume":"85","author":"Kaufman","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"joi230012r31","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/hep.31678","article-title":"Acute liver injury with therapeutic doses of acetaminophen: a prospective study.","volume":"73","author":"Louvet","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"joi230012r32","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.amepre.2011.02.016","article-title":"Developing consumer-centered, nonprescription drug labeling a study in acetaminophen.","volume":"40","author":"King","year":"2011","journal-title":"Am J Prev Med"},{"issue":"4","key":"joi230012r33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/emj.2007.053850","article-title":"Emergency department patient knowledge concerning acetaminophen (paracetamol) in over-the-counter and prescription analgesics.","volume":"25","author":"Fosnocht","year":"2008","journal-title":"Emerg Med J"},{"issue":"4","key":"joi230012r34","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1331\/JAPhA.2010.08175","article-title":"Survey of patient knowledge related to acetaminophen recognition, dosing, and toxicity.","volume":"50","author":"Hornsby","year":"2010","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"3","key":"joi230012r35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/pds.v22.3","article-title":"A survey of adult awareness and use of medicine containing acetaminophen.","volume":"22","author":"Boudreau","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"joi230012r36","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.japh.2018.06.012","article-title":"Knowledge of dosing directions among current users of acetaminophen-containing medications.","volume":"58","author":"Kelly","year":"2018","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"1","key":"joi230012r37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1331\/1544-3191.47.1.35.Stumpf","article-title":"Knowledge of appropriate acetaminophen doses and potential toxicities in an adult clinic population.","volume":"47","author":"Stumpf","year":"2007","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"15","key":"joi230012r38","doi-asserted-by":"publisher","first-page":"E542","DOI":"10.1503\/cmaj.210842","article-title":"Impact of acetaminophen product labelling changes in Canada on hospital admissions for accidental acetaminophen overdose: a population-based study.","volume":"194","author":"Antoniou","year":"2022","journal-title":"CMAJ"},{"issue":"6","key":"joi230012r39","doi-asserted-by":"publisher","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and geographic patterns in drug and synthetic opioid overdose deaths\u2014United States, 2013-2019.","volume":"70","author":"Mattson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"joi230012r40","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.mcna.2008.03.005","article-title":"Acute liver failure including acetaminophen overdose.","volume":"92","author":"Fontana","year":"2008","journal-title":"Med Clin North Am"},{"key":"joi230012r8","unstructured":"Newly reformulated Vicodin launch announcement. US Pharmacist. Published October 2012. Accessed June 5, 2022. https:\/\/www.uspharmacist.com\/email\/ecf1248.html"},{"key":"joi230012r12","unstructured":"FDA Drug Safety Communication. Prescription acetaminophen products to be limited to 325 mg per dosage unit; boxed warning will highlight potential for severe liver failure. US Food and Drug Administration. Published February 7, 2018. Accessed June 5, 2022. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-prescription-acetaminophen-products-be-limited-325-mg-dosage-unit"},{"key":"joi230012r13","unstructured":"Healthcare Cost and Utilization Project (HCUP), 2007-2019. Agency for Healthcare Research and Quality. Accessed September 14, 2022. http:\/\/www.hcup-us.ahrq.gov\/nisoverview.jsp"},{"key":"joi230012r22","unstructured":"Healthcare Cost and Utilization Project. Trend weights for HCUP NIS data. Agency for Healthcare Research and Quality. Published September 2014. Accessed July 15, 2022. http:\/\/www.hcup-us.ahrq.gov\/db\/nation\/nis\/trendwghts.jsp"},{"key":"joi230012r23","unstructured":"Healthcare Cost and Utilization Project. Producing national HCUP estimates. Agency for Healthcare Research and Quality. Accessed July 15, 2022. https:\/\/www.hcup-us.ahrq.gov\/tech_assist\/nationalestimates\/508_course\/508course_2018.jsp"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2802061\/jama_orandi_2023_oi_230012_1677717766.61307.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T11:31:54Z","timestamp":1678188714000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2802061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,3,7]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.1080","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,7]]}}}